Research Article



Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus

De-kang Zeng^{1,*}, Qian Xiao^{2,*}, Fa-qi Li², Yu-zhi Tang¹, Chao-li Jia³ and () Xue-wen Tang⁴

¹Department of Geriatrics, People's Hospital of Chongqing Banan District, Chongqing 401320, China; ²Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; ³Institute of Reproductive and Genetic, Chongqing Health Center for Women and Children, Chongqing 400010, China; ⁴Department of Cardiology, People's Hospital of Chongqing Banan District, Chongqing 401320, China

Correspondence: Xue-wen Tang (xuewentang401320@163.com)



Patients with type 2 diabetes mellitus (T2DM) have a very high risk of cardiovascular related events, and reducing complications is an important evaluation criterion of efficacy and safety of hypoglycemic drugs. Previous studies have shown that the dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP4i), such as sitagliptin, might reduce the incidence of major cardiovascular events (MACEs). However, the safety and efficacy of sitagliptin remains controversial, especially the safety for cardiovascular related events. Here, a systematic review was conducted to assess the cardiovascular safety of sitagliptin in T2DM patients. The literature research dating up to October 2018 was performed in the electronic database. The clinical trials about sitagliptin for T2DM patients were included. Two reviewers independently screened literature according to the inclusion and exclusion criteria. The primary outcome was the MACE, and the secondary outcome was all-cause mortality. Finally, 32 clinical trials composed of 16082 T2DM patients were included in this meta-analysis. The results showed that: there was no significant difference between sitagliptin group and the control group on MACE (odds ratio (OR) = 0.85, 95% confidence intervals (CIs) = 0.63-1.15), myocardial infarction (MI) (OR = 0.66, 95% CI = 0.38–1.16), stroke (OR = 0.83, 95% CI = 0.44–1.54) and mortality (OR = 0.52, 95% CI = 0.26–1.07). These results demonstrated that sitagliptin did not increase the risk of cardiovascular events in patients with T2DM.

Introduction

Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by insulin deficiency and insulin resistance. It is associated with a high risk of microvascular, cardiovascular and other complications (such as depression, a mental disorder with unclear pathogenesis) [1–4]. Most interventions for T2DM are designed to control the blood glucose level. However, these interventions pay little attention to other risk factors and rarely meet the multifaceted needs of patients with T2DM [5,6]. Currently, the main challenges of T2DM treatment include: maintaining tight glycemic control, minimizing the risk of hypoglycemia, controlling cardiovascular risk factors (such as blood pressure and serum lipid concentrations), and reducing or controlling weight. Diabetic patients suffer from a high rate of cardiovascular events. Therefore, the European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes and cardiovascular disease (CVD) emphasize the need for a stringent approach in treating patients with diabetes, suggesting the importance of reducing the cardiovascular events [7,8].

Dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP4i) are a pharmacological class of oral hypoglycemic drugs, which could prolong the action of the incretin peptide hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) by inhibiting their breakdown. Previous study suggested that DPP-4 inhibition might possibly have a beneficial cardiovascular effect in humans [9]. GLP-1 could suppress the release of glucagon from the pancreas. In addition, GLP-1 and GIP could also preserve or enhance β -cell function [10,11]. The levels of intact GLP-1 and GIP could decrease rapidly,

*These authors contributed equally to this work.

Received: 11 April 2019 Revised: 29 May 2019 Accepted: 18 June 2019

Accepted Manuscript Online: 01 July 2019 Version of Record published: 16 July 2019



due to enzymatic inactivation (mainly DPP-4) and renal clearance [12]. Sitagliptin, a potent and selective DPP4i, is specifically designed to extend the inhibition of DPP-4 enzyme. It could improve glycemic control through enhancing the action of GLP-1and GIP [13]. Fonseca et al. [14] reported that sitagliptin could improve glycemic control and be generally well tolerated by patients with T2DM.

Sitagliptin could better reduce the levels of low-density lipoprotein cholesterol and total cholesterol compared with pioglitazone [15]. Cornel et al. [16] reported that sitagliptin had no clinically significant impact on cardiovascular outcomes. However, whether sitagliptin has clinically significant impact on decreasing cardiovascular events or not is still controversial. Therefore, we conducted this work to assess the cardiovascular risk of sitagliptin in treating patients with T2DM.

Materials and methods Study selection

The literature research was conducted using the following scientific and medical databases: international databases (PubMed, Embase, Web of Science and Medline) and Chinese databases (CBM-disc, CNKI), which was up to October 2018. The search terms used were 'sitagliptin', 'diabetes', 'T2DM' and 'type 2 diabetes mellitus'. To avoid omitting relevant articles, no language was imposed, and reference documents listed in the included articles were also researched.

Among the articles identified in the initial research, only those meeting the following criteria were selected for subsequent analysis: (i) patients with T2DM; (ii) compared sitagliptin with placebo or active drugs (oral hypoglycaemic agents and/or insulin) different from other DPP4i; (iii) clinical trials with duration of at least 24 weeks. Potential articles meeting any one of the following criteria were excluded: (i) clinical trials with duration shorter than 24 weeks; (ii) patients with nondiabetic or type 1 diabetic; (iii) reviews, case reports and duplicate reports.

Data extraction and quality assessment

Two authors (De-kang Zeng and Yu-zhi Tang) of the present study served as reviewers to independently verify all potentially suitable clinical trials based on the aforementioned criteria, and extracted data subsequently. Any disagreement was resolved by the third reviewer. For all included articles, results reported in papers were used as the primary source of information. The primary outcome was major cardiovascular events (MACEs), including cardiovascular death, nonfatal myocardial infarction (MI) and stroke, and the secondary outcome was all-cause mortality.

Two authors (De-kang Zeng and Yu-zhi Tang) of the present study served as reviewers to independently assess the quality of each eligible study according to the Cochrane Collaboration criteria [17]. Bias risk was determined by: (i) randomization quality, (ii) allocation concealment, (iii) blinding of outcome assessment, (iv) incomplete reporting of outcome data, (v) similarity in baseline clinical characteristics. Studies with three or more bias risks were excluded from the meta-analysis.

Statistical analysis

This meta-analysis was conducted according to the recommendations of Sacks et al. [18]. Dichotomous data were preferred for clinical reasons. Baseline scores, standard deviations (SDs), and end point means were used to estimate the number of responsive patients under the condition that dichotomous efficacy outcomes were absent [19]. To perform a clinically sound analysis, a worst-case scenario analysis of drop-outs was used, under the assumption that all such patients did not respond to treatment [20]. The weighting of each study was performed according to the number of samples in each study. The meta-regression was used here to examine the impact of moderator variables, such as sex ratio and age, on the study effect size. Statistical analyses were performed using RevMan 5.3 (Cochrane Information Management System) and STATA software 8.0 (Stata Corporation, College Station, TX, U.S.A.). Heterogeneity was assessed using the Q statistic and I^2 [21]. A *P*-value <0.1 or I^2 value >50% indicated that there was significant statistical heterogeneity among the included studies. If there was heterogeneity, the pooled odds ratio (OR) and 95% confidence intervals (CIs) were calculated by Mantel–Haenszel fixed-effects model; otherwise, the random-effects model was used [22]. Finally, funnel plots and Egger's test were used to assess the potential presence of publication bias. This research was performed independently of any funding, as part of the institutional of the investigators.

Results Selected studies

The literature search yielded 1391 potentially relevant studies. However, only 32 studies met all the inclusion and exclusion criteria mentioned above [14,15,23–52], and could be used for subsequent analysis (Figure 1). Among these






Figure 1. Flow chart of the present study

studies, 12 studies were active comparator controlled and 20 studies were placebo controlled. Four studies did not report any adverse events and were excluded from the subsequent analysis. A total of 16082 patients with T2DM were included. Of these, 8536 patients were treated with sitagliptin and the remaining 7546 patients were treated with placebo or active drugs different from other DPP4i. Table 1 presented the detailed characteristics of the included studies.

MACEs

MACEs were reported in 28 studies. In these clinical trials, 86 of 8536 patients receiving sitagliptin and 82 of 7546 comparator patients reported MACE, respectively. The pooled OR was 0.85 (95% CI = 0.63-1.15, z = 1.04, *P* 0.30), indicating that there was no statistical difference between those two groups on the incidence of MACE. The risk of MACE was not significantly increased in patients receiving sitafliptin (Figure 2A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias (Figure 2B). Meanwhile, the results of Egger's test (*P*=0.54) also showed that our effect size was not influenced by these moderator variables.

The study period of two included studies was 104 weeks. Therefore, the sensitivity analysis was conducted by excluding these two studies. The new pooled OR was 0.89 (95% CI = 0.65–1.23, z = 0.69, *P*=0.49), which was similar to the original results. Meanwhile, the subgroup analysis was conducted according to the study period (\geq 54 and <54 weeks). The pooled OR of these studies with study period \geq 54 weeks was 1.16 (95% CI = 0.69–1.96, z = 0.57, *P*=0.57), and the pooled OR of these studies with study period <54 weeks was 0.73 (95% CI = 0.50–1.05, z = 1.69, *P*=0.09).



Table 1 Baseline characteristics of trials included in the meta-analysis

First author (year)	Sitagl	iptin				Control					
	n	Male	Female	Age (years)	BMI	n	Male	Female	Age (years)	BMI	
Henry (2014)	922	524	398	52.1 <u>+</u> 8.7	NR	693	388	305	51.5 <u>+</u> 9.2	NR	54
Chan (2008)	65	31	34	68.9 <u>+</u> 9.8	26.5 <u>+</u> 4.0	26	16	10	65.3 <u>+</u> 9.7	26.9 <u>+</u> 4.9	54
Ferreia (2013)	211	125	86	64.8 <u>+</u> 10.6	26.5 <u>+</u> 4.8	212	116	96	64.3 <u>+</u> 9.2	27.0 <u>+</u> 4.8	54
Williams (2010)	551	265	286	54.1 <u>+</u> 9.1	31.2 <u>+</u> 6.5	540	259	281	54.7 <u>+</u> 9.9	32.0 <u>+</u> 6.4	104
Charbonnel (2006)	464	259	205	54.4 <u>+</u> 10.4	30.9 <u>+</u> 5.3	237	141	96	54.7 <u>+</u> 9.7	31.5 <u>+</u> 4.9	24
Raz (2006)	411	214	197	55.4 <u>+</u> 9.2	31.9 <u>+</u> 5.3	110	69	41	55.5 <u>+</u> 10.1	32.5 ± 5.2	44
Aschner (2006)	488	253	235	54.1 <u>+</u> 9.8	30.3 ± 5.3	253	130	123	54.3 <u>+</u> 10.1	30.8 ± 5.5	24
Reasner (2011)	625	353	272	49.4 <u>+</u> 10.5	32.9 <u>+</u> 7.2	621	356	265	50.0 <u>+</u> 10.5	33.7 <u>+</u> 7.8	44
Visboll (2010)	322	157	165	58.3 ± 9.1	31 <u>+</u> 5	319	169	150	57.2 <u>+</u> 9.3	31 ± 5	24
Hermansen (2007)	222	117	105	55.6 + 9.6	31.2 + 6.3	219	117	102	56.5 + 9.6	30.7 + 6.3	24
Monteverde (2011)	244	152	92	50.5 <u>+</u> 10.9	30.3 ± 5.2	248	148	100	51.7 <u>+</u> 10.1	29.4 ± 5.2	40
Dobs (2013)	170	96	74	54.4 + 8.8	30.1 <u>+</u> 6.2	92	55	37	54.8 + 9.5	30.8 ± 5.6	54
Pratley (2012)	219	120	99			446	228	218			78
Arechavaleta (2011)	516	284	232			519	279	240			30
Yang (2012)	197	92	105			198	108	90		-25.3 ± 3.6	24
Bergenstal (2010)	166	86	80		32 ± 5	325	168	157			26
Aschner (2010)	528	217	311			522	194	328			24
Wainstein (2012)	261	143	118			256	134	122			32
Seck (2010)	588	336	252		30.9 + 4.8	584	367	217		31.3 ± 5.0	104
Yoon (2011)	261	137	124			259	145	114			24
Fonseca (2013)	157	97	60		29.9 + 5.2	156	98	58	56.4 + 9.4	30.0 + 5.2	26
Barzilai (2011)	102	48	54		$-$ 30.8 \pm 5.9	104	49	55			24
Yoon (2012)	164	86	78		29.7 + 4.8	153	90	63		29.9 + 5.3	24
Raz (2008)	96	49	47	53.6 + 9.5	30.4 + 5.3	94	39	55	56.1 + 9.5	30.1 ± 4.4	30
Rosenstock (2006)	175	93	82		32.0 ± 5.2	178	103	75		31.0 + 5.0	24
Stein (2014)	10	6	4	61.3 + 8.2	34.3 + 3.3	11	8	3	60.8 + 7.6	32.7 + 2.7	48
Zang (2016)	184	117	67	51.4 ± 11.0	27.2 ± 4.0	183	102	81	51.7 ± 10.7	27.3 ± 3.4	26
<im (2017)<="" td=""><td>147</td><td>81</td><td>66</td><td></td><td> 25.2 + 2.7</td><td>145</td><td>84</td><td>61</td><td>53.1 + 9.2</td><td>25.0 + 2.8</td><td>30</td></im>	147	81	66		 25.2 + 2.7	145	84	61	53.1 + 9.2	25.0 + 2.8	30
Ji (2016)	120	74	46	51.7 ± 10.2	26.0 ± 3.5	126	69	57	52.6 ± 9.5	26.0 ± 3.7	24
Ba (2016)	249	117	132	57.5 ± 9.5	25.4 ± 3.2	249	132	117	56.5 ± 9.3	25.3 ± 3.2	24
Shankar (2016)	234	130	104	58.6 ± 8.4	25.9 ± 3.0	233	116	117	56.7 ± 9.1	26.1 <u>+</u> 2.9	24
Duan (2016)	105	59	46	50.32 + 3.21	27.10 + 1.73	103	55	48	48.88 + 2.91	27.32 + 1.81	24

Abbreviations: BMI, body mass index; *n*, number; NR, not available.

These results indicated that our conclusion was not significantly influenced by the different treatment periods. The subgroup analysis was also conducted according to the different sorts of control groups (sitagliptin vs. placebo and sitagliptin vs. active drugs). The pooled OR of sitagliptin vs. placebo was 0.73 (95% CI = 0.49-1.09, z = 1.55, *P*=0.12), and the pooled OR of sitagliptin vs. active drugs was 1.05 (95% CI = 0.66-1.68, z = 0.22, *P*=0.83). These results indicated that our conclusion was not significantly influenced by the different sorts of control groups.

Μ

MI was reported in 16 studies. In these clinical trials, 19 of 6073 patients receiving sitagliptin and 22 of 4935 comparator patients reported MI, respectively. The pooled OR was 0.66 (95% CI = 0.38-1.16, z = 1.44, *P*=0.15), indicating that there was no statistical difference between those two groups on the incidence of MI. The risk of MI was not significantly increased in patients receiving sitafliptin (Figure 3A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias (Figure 3B). Meanwhile, the results of Egger's test (*P*=0.47) also showed that the outcome was not influenced by the potential publication bias.



(A)							Odds Ratio (B)
	Sitaglip		Contr			Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H. Fixed. 95% Cl 0 T
Arechavaleta 2011	2	516	2	519	2.2%	1.01 [0.14, 7.17]	
Aschner 2006	5	488	7	253	10.0%	0.36 [0.11, 1.16]	
Aschner 2010	1	528	1	522	1.1%	0.99 [0.06, 15.85]	
BA 2016	0	249	3	249	3.8%	0.14 [0.01, 2.75]	
Barzilai 2011	0	102	1	104	1.6%	0.34 [0.01, 8.36]	
Bergenstal 2010	1	166	4	325	3.0%	0.49 [0.05, 4.39]	
Chan 2008	10	65	1	26	1.3%	4.55 [0.55, 37.47]	
Charbonnel 2006	6	464	4	237	5.7%	0.76 [0.21, 2.73]	0.5
Dobs 2013	3	170	0	92	0.7%	3.87 [0.20, 75.65]	
Duan 2016	1	105	7	103	7.7%	0.13 [0.02, 1.09]	
Ferreia 2013	7	211	10	212	10.6%	0.69 [0.26, 1.86]	
Fonseca 2013	0	157	1	156	1.6%	0.33 [0.01, 8.14]	· · · · · · · · · · · · · · · · · · ·
Henry 2014	10	922	2	693	2.5%	3.79 [0.83, 17.35]	
Hermansen 2007	3	222	3	219	3.3%	0.99 [0.20, 4.94]	
Ji 2016	1	120	0	126	0.5%	3.18 [0.13, 78.72]	
Kim 2017	8	147	9	145	9.4%	0.87 [0.33, 2.32]	
Monteverde 2011	3	244	0	248	0.5%	7.20 [0.37, 140.18]	
Raz 2006	6	411	0	110	0.9%	3.54 [0.20, 63.37]	
Raz 2008	0	96	1	94	1.7%	0.32 [0.01, 8.03]	
Reasner 2011	5	625	6	621	6.6%	0.83 [0.25, 2.72]	
Seck 2010	0	588	4	584	5.0%	0.11 [0.01, 2.04]	
Visboll 2010	3	322	5	319	5.5%	0.59 [0.14, 2.49]	
Wainstein 2012	1	261	0	256	0.6%	2.95 [0.12, 72.85]	
Williams 2010	7	551	8	540	8.8%	0.86 [0.31, 2.38]	
Yang 2012	2	197	0	198	0.5%	5.08 [0.24, 106.43]	
Yoon 2011	0	261	2	259	2.8%	0.20 [0.01, 4.12]	
Yoon 2012	0	164	1	153	1.7%	0.31 [0.01, 7.64]	
Zang 2016	1	184	0	183	0.5%	3.00 [0.12, 74.13]	
Total (95% CI)		8536		7546	100.0%	0.85 [0.63, 1.15]	
Total events	86		82				OR
Heterogeneity: Chi ² = 2				!= 0%			0.01 0.1 1 10 100 2 0.1 10
Test for overall effect: 2	Z = 1.04 (F	P = 0.3	0)				Favours Sitagliptin Favours Control 0.1 1 10

Figure 2. Number of patients with MACEs in two groups

(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.




Figure 3. Number of patients with MI in two groups

(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.

Stroke

Stroke was reported in 16 studies. In these clinical trials, 15 of 5329 patients receiving sitagliptin and 14 of 4421 comparator patients reported stroke, respectively. The pooled OR was 0.83 (95% CI = 0.44-1.54, z = 0.59, *P*=0.55), indicating that there was no statistical difference between those two groups on the incidence of stroke. The risk of stroke was not significantly increased in patients receiving sitafliptin (Figure 4A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias (Figure 4B). Meanwhile, the results of Egger's test (*P*=0.26) also showed that the outcome was not influenced by the potential publication bias.

Mortality

There were eight studies reported information on mortality (either cardiovascular death or others). In these clinical trials, 12 of 2659 patients receiving sitagliptin and 19 of 2375 comparator patients experienced death, respectively. The pooled OR was 0.52 (95% CI = 0.26-1.07, z = 1.78, *P*=0.07), indicating that there was no statistical difference between those two groups on the incidence of mortality. The risk of mortality was not significantly increased in patients receiving sitafliptin (Figure 5A). The funnel plot of these studies appeared to be closely symmetrical, which indicated that there was no publication bias (Figure 5B). Meanwhile, the results of Egger's test (*P*=0.30) also showed that the outcome was not influenced by the potential publication bias.



Sitaglin	otin	Contro	al		Odds Ratio		Odds Ratio	(B)		
				Weight					T SE(log(OR)	
0	516	2	519	11.5%	0.20 [0.01, 4.18]				/	N
1	65	0	26	3.2%	1.23 [0.05, 31.23]			-	/	
2	464	0	237	3.0%	2.57 [0.12, 53.70]			_	/	I N
1	170	0	92	3.0%	1.64 [0.07, 40.59]			_	/	1
0	105	2	103	11.6%	0.19 [0.01, 4.06]	•		0.5	+ /	
2	211	1	212	4.6%	2.02 [0.18, 22.44]				/	1
1	922	2	693	10.6%	0.38 [0.03, 4.15]	-			/	
2	222	1	219	4.6%	1.98 [0.18, 22.02]				1	N.
2	411	0	110	3.6%	1.35 [0.06, 28.31]				/	
0	625	2	621	11.6%	0.20 [0.01, 4.13]	-		1	1 /	
1	261	0	256	2.3%	2.95 [0.12, 72.85]				/	
0	551	2	540	11.7%	0.20 [0.01, 4.08]	•			/ .	
2	197	0	198	2.3%	5.08 [0.24, 106.43]				/ "	
0	261	1	259	7.0%	0.33 [0.01, 8.13]				1	N.
0	164	1	153	7.2%	0.31 [0.01, 7.64]				1 <i>i</i>	1
1	184	0	183	2.3%	3.00 [0.12, 74.13]			1.5	T / D	000 \
									/ 0	000
	5329		4421	100.0%	0.83 [0.44, 1.54]		-		1	\ \
15		14							1	
			: 0%			0.01	0.1 1 10	100	/	OR
Z = 0.59 (F	P = 0.5	5)							0.1	1 10
	Events 0 1 1 2 1 0 2 1 2 2 0 1 1 2 2 0 0 1 1 0 2 0 0 1 1 9.02, df = 1 5 9.02, df = 1 5	0 516 1 65 2 464 1 170 0 105 2 211 1 922 2 211 0 625 1 261 0 551 2 197 0 261 0 164 1 184 5329 9.02, df = 15 (P =	Events Total Events 0 516 2 1 65 0 2 464 0 1 170 0 0 105 2 2 211 1 1 922 2 2 211 1 2 212 1 2 411 0 0 625 2 1 261 0 0 261 1 0 164 1 1 184 0 5329 15 14	Usernits Total Events Total 0 516 2 516 2 65 0 26 2 464 0 237 1 170 0 92 0 105 2 103 2 211 1 212 1 922 2 693 2 221 191 219 2 411 0 110 0 625 2 621 1 261 0 256 0 551 2 540 2 197 198 0 261 1289 0 164 1 153 1 184 0 183 5329 4421 15 14 9.02, df = 15 (P = 0.88); P = 0% 19 10 19 10 12 14 14 14 14 14 14 <t< td=""><td>Events Total Events Total Weight 0 516 2 519 11.5% 1 65 0 26 3.2% 2 464 0 237 3.0% 1 170 0 92 3.0% 0 105 2 103 11.6% 2 211 1 212 4.6% 2 221 113 1.4% 2 222 623 10.6% 2 221 1219 4.6% 2 221 219 10 3.6% 0 625 2 621 11.6% 0 551 2 540 11.7% 2 197 0 198 2.3% 0 261 1 2.5% 7.0% 0 184 1 183 7.2% 1 184 0 183 2.3% 5329 4421 100.0%</td><td>Events Total Weight M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 (0.01, 4.18) 1 65 0 26 3.2% 0.20 (0.01, 4.18) 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 1.64 (0.07, 40.59) 0 105 2 103 11.6% 0.38 [0.03, 4.15] 2 221 11 212 4.6% 2.02 [0.18, 22.44] 1 922 2 303 10.6% 0.38 [0.03, 4.15] 2 222 1 219 4.6% 1.98 [0.16, 22.02] 2 411 0 10.36% 0.32 [0.01, 4.13] 0 625 2 621 11.6% 0.20 [0.01, 4.08] 1 261 0 2.5% 0.33 [0.01, 8.13] 0.20 [0.01, 4.08] 2 197 0 198 2.3% 5.08 [0.24, 106.43] 0 261</td><td>Events Total Events Total Weight M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 [0.01, 4.18] 1 65 0 26 3.2% 1.23 [0.05, 31.23] 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 2.57 [0.12, 53.70] 0 105 2 103 11.6% 0.19 [0.01, 4.06] 2 211 212 4.6% 2.02 [0.18, 22.44] 1 922 2 693 10.6% 0.38 [0.03, 4.15] 2 211 110 3.6% 0.38 [0.03, 4.15] 2 222 103 11.6% 0.20 [0.1, 4.13] 0 625 2 621 1.38 [0.06, 28.31] 0 625 2 621 1.7% 0.20 [0.01, 4.08] 2 197 198 2.3% 5.08 [0.24, 106.43] 0.20 [0.1, 76.4] 1 184</td><td>Events Total Weight M-H. Fixed. 95% CI M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 [0.01, 4.18] 1 65 0 26 3.2% 1.23 [0.05, 31.23] 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 1.64 [0.07, 40.59] 0 105 2 103 1.64 [0.07, 40.59] 1 170 0 92 3.0% 0.18 [2.2.02] 2 11 212 4.6% 0.18 [0.01, 4.05] 2 211 10 3.6% 0.38 [0.03, 4.15] 2 222 1 219 4.6% 0.20 [0.01, 4.13] 0 625 2 621 11.6% 0.20 [0.01, 4.08] 1 2461 1 2.58 [0.2.4% (0.6.43] 0.33 [0.01, 4.08] 0 15 2.5% 7.0% (0.33 [0.01, 4.08] 0.33 [0.01, 4.08] 0.33 [0.01, 4.08] 1 184 <t< td=""><td>Events Total Weight M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0 0 516 2 519 11.5% 0.20 [0.01, 4.18] 0 1 65 0 26 3.2% 1.23 [0.05, 31.23] 0 2 464 0 237 3.0% 2.57 [0.12, 53.70] 0 1 170 0 92 3.0% 1.64 [0.07, 40.59] 0 0 105 2 103 11.6% 0.19 [0.01, 4.06] 0.5 2 211 1 122 4.6% 2.02 [0.18, 22.44] 0.5 2 222 1 219 4.6% 1.98 [0.18, 22.02] 0.4 2 2411 0 10 0.38 [0.03, 4.15] 0.4 1 265 2 621 1.8% 0.20 [0.01, 4.13] 1.5 0 625 2 621 1.8% 0.20 [0.01, 4.13] 1.5 1 261 0.25% 0.33 [0.012, 74.163 <t< td=""><td>Events Total Events Total Weight M-H. Fixed, 95% CI M-H. Fixed, 95% CI M-H. Fixed, 95% CI 0 0 516 2 519 11.5% 0.20 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.06) 0.22 (0.01, 4.06) 0.54 0.54 1 105 2 103 11.6% 0.19 [0.01, 4.06] 0.54 0.54 2 211 1 212 4.6% 0.20 [0.01, 4.13] 0.54 0.54 2 211 0 0.56 0.23% (0.01, 4.13) 0.54 0.54 2 2222 1 116% 0.20 [0.01, 4.13] 0.54 0.54 2 2411 0 105 0.23 [0.01, 8.23 (0.12, 72.86) 0.54 0.54 0 515 2.540 11.7% 0.23 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.53 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.55 0.56 0.55 0.56</td></t<></td></t<></td></t<>	Events Total Events Total Weight 0 516 2 519 11.5% 1 65 0 26 3.2% 2 464 0 237 3.0% 1 170 0 92 3.0% 0 105 2 103 11.6% 2 211 1 212 4.6% 2 221 113 1.4% 2 222 623 10.6% 2 221 1219 4.6% 2 221 219 10 3.6% 0 625 2 621 11.6% 0 551 2 540 11.7% 2 197 0 198 2.3% 0 261 1 2.5% 7.0% 0 184 1 183 7.2% 1 184 0 183 2.3% 5329 4421 100.0%	Events Total Weight M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 (0.01, 4.18) 1 65 0 26 3.2% 0.20 (0.01, 4.18) 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 1.64 (0.07, 40.59) 0 105 2 103 11.6% 0.38 [0.03, 4.15] 2 221 11 212 4.6% 2.02 [0.18, 22.44] 1 922 2 303 10.6% 0.38 [0.03, 4.15] 2 222 1 219 4.6% 1.98 [0.16, 22.02] 2 411 0 10.36% 0.32 [0.01, 4.13] 0 625 2 621 11.6% 0.20 [0.01, 4.08] 1 261 0 2.5% 0.33 [0.01, 8.13] 0.20 [0.01, 4.08] 2 197 0 198 2.3% 5.08 [0.24, 106.43] 0 261	Events Total Events Total Weight M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 [0.01, 4.18] 1 65 0 26 3.2% 1.23 [0.05, 31.23] 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 2.57 [0.12, 53.70] 0 105 2 103 11.6% 0.19 [0.01, 4.06] 2 211 212 4.6% 2.02 [0.18, 22.44] 1 922 2 693 10.6% 0.38 [0.03, 4.15] 2 211 110 3.6% 0.38 [0.03, 4.15] 2 222 103 11.6% 0.20 [0.1, 4.13] 0 625 2 621 1.38 [0.06, 28.31] 0 625 2 621 1.7% 0.20 [0.01, 4.08] 2 197 198 2.3% 5.08 [0.24, 106.43] 0.20 [0.1, 76.4] 1 184	Events Total Weight M-H. Fixed. 95% CI M-H. Fixed. 95% CI 0 516 2 519 11.5% 0.20 [0.01, 4.18] 1 65 0 26 3.2% 1.23 [0.05, 31.23] 2 464 0 237 3.0% 2.57 [0.12, 53.70] 1 170 0 92 3.0% 1.64 [0.07, 40.59] 0 105 2 103 1.64 [0.07, 40.59] 1 170 0 92 3.0% 0.18 [2.2.02] 2 11 212 4.6% 0.18 [0.01, 4.05] 2 211 10 3.6% 0.38 [0.03, 4.15] 2 222 1 219 4.6% 0.20 [0.01, 4.13] 0 625 2 621 11.6% 0.20 [0.01, 4.08] 1 2461 1 2.58 [0.2.4% (0.6.43] 0.33 [0.01, 4.08] 0 15 2.5% 7.0% (0.33 [0.01, 4.08] 0.33 [0.01, 4.08] 0.33 [0.01, 4.08] 1 184 <t< td=""><td>Events Total Weight M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0 0 516 2 519 11.5% 0.20 [0.01, 4.18] 0 1 65 0 26 3.2% 1.23 [0.05, 31.23] 0 2 464 0 237 3.0% 2.57 [0.12, 53.70] 0 1 170 0 92 3.0% 1.64 [0.07, 40.59] 0 0 105 2 103 11.6% 0.19 [0.01, 4.06] 0.5 2 211 1 122 4.6% 2.02 [0.18, 22.44] 0.5 2 222 1 219 4.6% 1.98 [0.18, 22.02] 0.4 2 2411 0 10 0.38 [0.03, 4.15] 0.4 1 265 2 621 1.8% 0.20 [0.01, 4.13] 1.5 0 625 2 621 1.8% 0.20 [0.01, 4.13] 1.5 1 261 0.25% 0.33 [0.012, 74.163 <t< td=""><td>Events Total Events Total Weight M-H. Fixed, 95% CI M-H. Fixed, 95% CI M-H. Fixed, 95% CI 0 0 516 2 519 11.5% 0.20 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.06) 0.22 (0.01, 4.06) 0.54 0.54 1 105 2 103 11.6% 0.19 [0.01, 4.06] 0.54 0.54 2 211 1 212 4.6% 0.20 [0.01, 4.13] 0.54 0.54 2 211 0 0.56 0.23% (0.01, 4.13) 0.54 0.54 2 2222 1 116% 0.20 [0.01, 4.13] 0.54 0.54 2 2411 0 105 0.23 [0.01, 8.23 (0.12, 72.86) 0.54 0.54 0 515 2.540 11.7% 0.23 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.53 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.55 0.56 0.55 0.56</td></t<></td></t<>	Events Total Weight M-H. Fixed. 95% Cl M-H. Fixed. 95% Cl 0 0 516 2 519 11.5% 0.20 [0.01, 4.18] 0 1 65 0 26 3.2% 1.23 [0.05, 31.23] 0 2 464 0 237 3.0% 2.57 [0.12, 53.70] 0 1 170 0 92 3.0% 1.64 [0.07, 40.59] 0 0 105 2 103 11.6% 0.19 [0.01, 4.06] 0.5 2 211 1 122 4.6% 2.02 [0.18, 22.44] 0.5 2 222 1 219 4.6% 1.98 [0.18, 22.02] 0.4 2 2411 0 10 0.38 [0.03, 4.15] 0.4 1 265 2 621 1.8% 0.20 [0.01, 4.13] 1.5 0 625 2 621 1.8% 0.20 [0.01, 4.13] 1.5 1 261 0.25% 0.33 [0.012, 74.163 <t< td=""><td>Events Total Events Total Weight M-H. Fixed, 95% CI M-H. Fixed, 95% CI M-H. Fixed, 95% CI 0 0 516 2 519 11.5% 0.20 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.06) 0.22 (0.01, 4.06) 0.54 0.54 1 105 2 103 11.6% 0.19 [0.01, 4.06] 0.54 0.54 2 211 1 212 4.6% 0.20 [0.01, 4.13] 0.54 0.54 2 211 0 0.56 0.23% (0.01, 4.13) 0.54 0.54 2 2222 1 116% 0.20 [0.01, 4.13] 0.54 0.54 2 2411 0 105 0.23 [0.01, 8.23 (0.12, 72.86) 0.54 0.54 0 515 2.540 11.7% 0.23 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.53 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.55 0.56 0.55 0.56</td></t<>	Events Total Events Total Weight M-H. Fixed, 95% CI M-H. Fixed, 95% CI M-H. Fixed, 95% CI 0 0 516 2 519 11.5% 0.20 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.16) 0.21 (0.01, 4.06) 0.22 (0.01, 4.06) 0.54 0.54 1 105 2 103 11.6% 0.19 [0.01, 4.06] 0.54 0.54 2 211 1 212 4.6% 0.20 [0.01, 4.13] 0.54 0.54 2 211 0 0.56 0.23% (0.01, 4.13) 0.54 0.54 2 2222 1 116% 0.20 [0.01, 4.13] 0.54 0.54 2 2411 0 105 0.23 [0.01, 8.23 (0.12, 72.86) 0.54 0.54 0 515 2.540 11.7% 0.23 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.53 [0.01, 8.13 (0.14, 76.43) 0.53 [0.01, 8.13 (0.14, 76.43) 0.55 0.55 0.56 0.55 0.56

Figure 4. Number of patients with stroke in two groups

(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.




Figure 5. Number of mortality in two groups

(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.

Discussion

With more than 300 million patients with T2DM in the whole world, as drugs for T2DM, it is not only important to manage the blood glucose but also control the risk of complications, especially decreasing cardiovascular risk [53,54]. So the analysis of serious adverse events in clinical trials is essential for assessing the safety profile of newer drugs. Sitagliptin, as a representative drug of DPP4i, is usually used for treating T2DM. By slowing incretin degradation, DPP4i enhance meal-stimulated active GLP-1 and GIP levels by two- to threefold. When the blood glucose concentration is elevated, GLP-1 and GIP can increase the pancreatic β -cell synthesis and release insulin by increasing intracellular signaling pathways. Sitagliptin could be able to increase the concentration of GLP-1 and GIP [13].

Previous study suggested that sitagliptin could play a role in modifying the high risk of fatal arrhythmias that are inherent in T2DM [55]. However, the efficacy of sitagliptin for T2DM complications remains uncertain. Previous pooled analyses of individual compounds have yielded discordant results, with incidence of cardiovascular events either reduced or unchanged [56,57]. Our results found that the use of sitagliptin would not increase the risk of MACE compared with placebo or other hypoglycemic drugs. The strength of this conclusion was the large number of trials with a large number of patients, and the present meta-analysis confirmed the trend reported in the previous study [57]. We also found that the incidences of MI and stroke were not significantly increased in patients receiving sitagliptin.

Sitagliptin is mostly excreted as unchanged drug by kidney; then, the renal insufficiency would increase the circulating levels of sitagliptin [58]. In contrast, vildagliptin is primarily metabolized by hydrolysis to an inactive compound; then, only approximately 20% of vildagliptin is excreted unchanged [59]. In addition, saxagliptin is mainly metabolized by liver to an active compound; then itself and its metabolites are renally excreted [60]. Many studies have shown that sitagliptin and vildagliptin were comparable on safety and tolerability, both in short-term and long-term treatments [61,62]. Although experience with saxagliptin is more limited, some studies also reported that this drug was tolerable and safe [60,63].

Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for treating diabetes. Nowadays, six kinds of SGLT2 (tofogliflozin, canagliflozin, empagliflozin, dapagliflozin, ipragliflozin, and



luseogliflozin) for diabetes are approved. The common adverse events of SGLT2 include: reproductive system infection, urinary system infection, and ketoacidosis [64]. The common adverse event of sitagliptin is gastrointestinal reaction (such as abdominal pain, diarrhea, nausea, vomiting). As the second- and third-line medication for T2DM, SGLT2 can be used in combination with metformin or other hypoglycemic agents.

The main limitation of the present study was that the dosage of sitagliptin in each study was not the same, which might influence the results of this meta-analysis. However, this limitation was also the general problem for meta-studies to solve. Meanwhile, the main purpose of the existing studies about sitagliptin was to assess the efficacy, tolerability, and safety of blood glucose control. The final conclusion about the influence of sitagliptin on cardiovas-cular risk in T2DM patients still needs future studies to further investigate, especially the large-scale clinical trials. Finally, a double-blind, controlled, randomized, multi-center study would be needed to highlight the usefulness of sitagliptin and other gliptins. In conclusion, available data from these short- and medium-term trials showed that treatment with sitagliptin did not increase the risk of cardiovascular events in patients with T2DM.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Author Contribution

De-kang Zeng and Xue-wen Tang designed the present study. De-kang Zeng, Qian Xiao and Yu-zhi Tang conducted the literature research, data extraction and quality assessment. Qian Xiao, Fa-qi Li, and Chao-li Jia conducted the statistical analysis. De-kang Zeng and Xue-wen Tang prepared the manuscript. Qian Xiao, Fa-qi Li and Xue-wen Tang revised the manuscript. All authors made significant contribution to the present study.

Funding

The authors declare that there are no sources of funding to be acknowledged.

Abbreviations

CI, confidence interval; DPP-4, dipeptidyl peptidase-4; DPP4i, DPP-4 inhibitor; GIP, glucose-dependent insulinotropic polypeptide; GLP, glucagon-like peptide; MACE, major cardiovascular event; MI, myocardial infarction; OR, odds ratio; SGLT2, sodium-dependent glucose transporter 2; T2DM, type 2 diabetes mellitus.

References

- 1 Skovgaard, R., Ploug, U.J., Hunt, B. et al. (2015) Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. *Clin. Ther.* **37**, 1677–1688, https://doi.org/10.1016/j.clinthera.2015.05.496
- 2 Strain, W.D., Agarwal, A.S. and Paldánius, P.M. (2017) Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. *Aging* 9, 769–777, https://doi.org/10.18632/aging.101188
- 3 Chen, J., Bai S, J., Li, W. et al. (2018) Urinary biomarker panel for diagnosing patients with depression and anxiety disorders. *Transl. Psychiatry* 8, 192, https://doi.org/10.1038/s41398-018-0245-0
- 4 Chen, J., Xie, J., Zeng, L. et al. (2019) Urinary metabolite signature in bipolar disorder patients during depressive episode. *Aging* **11**, 1008–1018, https://doi.org/10.18632/aging.101805
- 5 Xie, J., Li, N., Jiang, X. et al. (2019) Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus. *Diabetes Metab. Syndr. Obes.* **12**, 519–526, https://doi.org/10.2147/DMS0.S198154
- 6 Montesanto, A., Bonfigli, A.R., Crocco, P. et al. (2018) Genes associated with type 2 diabetes and vascular complications. *Aging* **10**, 178–196, https://doi.org/10.18632/aging.101375
- 7 Holman, R.R., Sourij, H. and Califf, R.M. (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. *Lancet* **383**, 2008–2017, https://doi.org/10.1016/S0140-6736(14)60794-7
- 8 Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N. et al. (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur. Heart J.* **34**, 3035–3087, https://doi.org/10.1093/eurheartj/eht108
- 9 Sato, A., Yoshihisa, A., Kanno, Y., Takiguchi, M., Miura, S., Shimizu, T. et al. (2016) Associations of dipeptidal peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. *ESC Heart Fail.* **3**, 77–85, https://doi.org/10.1002/ehf2.12079
- 10 Barnett, A. (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int. J. Clin. Pract.* **60**, 1454–1470, https://doi.org/10.1111/j.1742-1241.2006.01178.x
- 11 Rathmann, W., Kostev, K. and Haastert, B. (2007) Glycemic durability of monotherapy for diabetes. N. Engl. J. Med. 356, 1378–1379, https://doi.org/10.1056/NEJMc063760
- 12 Wang, L., Li, P., Tang, Z., Yan, X. and Feng, B. (2016) Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. *Sci. Rep.* **6**, 33251, https://doi.org/10.1038/srep33251



- 13 Herman, G.A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P. et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.* **91**, 4612–4619, https://doi.org/10.1210/jc.2006-1009
- 14 Fonseca, V., Staels, B., Morgan, II, J.D., Shentu, Y., Golm, G.T., Johnson-Levonas, A.O. et al. (2013) Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J. Diabetes Complications 27, 177–183, https://doi.org/10.1016/j.jdiacomp.2012.09.007
- 15 Perez-Monteverde, A., Seck, T., Xu, L., Lee, M.A., Sisk, C.M., Williams-Herman, D.E. et al. (2011) Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. *Int. J. Clin. Pract.* **65**, 930–938, https://doi.org/10.1111/j.1742-1241.2011.02749.x
- 16 Cornel, J.H., Bakris, G.L., Stevens, S.R. et al. (2016) Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. *Diabetes Care* **39**, 2304–2310, https://doi.org/10.2337/dc16-1415
- 17 Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D. et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* **343**, d5928, https://doi.org/10.1136/bmj.d5928
- 18 Sacks, H.S., Berrier, J., Reitman, D., Ancona-Berk, V.A. and Chalmers, T.C. (1987) Meta-analyses of randomized controlledtrials. *N. Engl. J. Med.* **316**, 450–455, https://doi.org/10.1056/NEJM198702193160806
- 19 Furukawa, T.A., Cipriani, A., Barbui, C., Brambilla, P. and Watanabe, N. (2005) Imputing response rates from means and standard deviations in meta-analyses. *Int. Clin. Psychopharmacol.* **20**, 49–52, https://doi.org/10.1097/00004850-200501000-00010
- 20 Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R. et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* **373**, 746–758, https://doi.org/10.1016/S0140-6736(09)60046-5
- 21 Chen, J., Zhou, C., Wu, B. et al. (2013) Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomised controlled trials. *Psychiatry Res.* **210**, 1260–1264, https://doi.org/10.1016/j.psychres.2013.09.007
- 22 DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. Control Clin. Trials 7, 177-188, https://doi.org/10.1016/0197-2456(86)90046-2
- 23 Pratley, R.E., Nauck, M.A., Bailey, T. et al. (2012) Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. *Diabetes Care* 35, 1986–1993, https://doi.org/10.2337/dc11-2113
- 24 Rosenstock, J., Brazg, R., Andryuk, P.J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin. Ther.* 28, 1556–1568, https://doi.org/10.1016/j.clinthera.2006.10.007
- 25 Stein, C.M., Kramer, C.K., Zinman, B. et al. (2015) Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes. *Diabetes Med.* **32**, 645–652, https://doi.org/10.1111/dme.12671
- 26 Shankar, R.R., Bao, Y., Han, P. et al. (2017) Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. J. Diabetes Investig. 8, 321–329, https://doi.org/10.1111/jdi.12585
- 27 Arechavaleta, R., Seck, T., Chen, Y. et al. (2011) Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. *Diabetes Obes. Metab.* **13**, 160–168, https://doi.org/10.1111/j.1463-1326.2010.01334.x
- 28 Bergenstal, R.M., Wysham, C., MacConell, L. et al. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet North Am. Ed.* **376**, 431–439, https://doi.org/10.1016/S0140-6736(10)60590-9
- 29 Aschner, P., Kipnes, M.S., Lunceford, J.K. et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* **29**, 2632–2637, https://doi.org/10.2337/dc06-0703
- 30 Aschner, P., Katzeff, H.L., Guo, H. et al. (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes Obes. Metab.* **12**, 252–261, https://doi.org/10.1111/j.1463-1326.2009.01187.x
- 31 Ba, J., Han, P., Yuan, G. et al. (2017) Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J. Diabetes 9, 667–676, https://doi.org/10.1111/1753-0407.12456
- 32 Barzilai, N., Guo, H., Mahoney, E.M. et al. (2011) Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Curr. Med. Res. Opin.* **27**, 1049–1058, https://doi.org/10.1185/03007995.2011.568059
- 33 Chan, J.C.N., Scott, R., Arjona Ferreira, J.C. et al. (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes. Metab.* **10**, 545–555, https://doi.org/10.1111/j.1463-1326.2008.00914.x
- 34 Charbonnel, B., Karasik, A., Liu, J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* **29**, 2638–2643, https://doi.org/10.2337/dc06-0706
- 35 Dobs, A.S., Goldstein, B.J., Aschner, P. et al. (2013) Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. *J. Diab.* **5**, 68–79, https://doi.org/10.1111/j.1753-0407.2012.00223.x
- 36 Duan, J.T., Peng, D.Q., Dong, B. et al. (2016) Effect of sitagliptin plus melbine on blood glucose and incidence rate of cardiovascular events in patients with type 2 diabetes mellitus. J. Clin. Med. Pract. 20, 18–21
- 37 Ferreira, J.C.A., Marre, M., Barzilai, N. et al. (2013) Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. *Diabetes Care* **36**, 1067–1073, https://doi.org/10.2337/dc12-1365
- 38 Henry, R.R., Staels, B., Fonseca, V.A. et al. (2014) Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study. *Diabetes Obes. Metab.* **16**, 223–230, https://doi.org/10.1111/dom.12194



- 39 Hermansen, K., Kipnes, M., Luo, E. et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes. Metab.* 9, 733–745, https://doi.org/10.1111/j.1463-1326.2007.00744.x
- 40 Ji, L., Han, P., Wang, X. et al. (2016) Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J. Diabetes Investig. **7**, 727–736, https://doi.org/10.1111/jdi.12511
- 41 Kim, S.S., Kim, I.J., Lee, K.J. et al. (2017) Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. J. Diabetes 9, 412–422, https://doi.org/10.1111/1753-0407.12432
- 42 Raz, I., Hanefeld, M., Xu, L. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* **49**, 2564–2571, https://doi.org/10.1007/s00125-006-0416-z
- 43 Raz, I., Chen, Y., Wu, M. et al. (2008) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr. Med. Res. Opin.* 24, 537–550, https://doi.org/10.1185/030079908X260925
- 44 Reasner, C., Olansky, L., Seck, T.L. et al. (2011) The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. *Diabetes Obes. Metab.* **13**, 644–652, https://doi.org/10.1111/j.1463-1326.2011.01390.x
- 45 Seck, T., Nauck, M., Sheng, D. et al. (2010) Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int. J. Clin. Pract. 64, 562–576, https://doi.org/10.1111/j.1742-1241.2010.02353.x
- 46 Vilsbøll, T., Rosenstock, J., Yki-Järvinen, H. et al. (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes. Metab.* **12**, 167–177, https://doi.org/10.1111/j.1463-1326.2009.01173.x
- 47 Wainstein, J., Katz, L., Engel, S.S. et al. (2012) Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. *Diabetes Obes. Metab.* **14**, 409–418, https://doi.org/10.1111/j.1463-1326.2011.01530.x
- 48 Williams-Herman, D., Johnson, J., Teng, R. et al. (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. *Diabetes Obes. Metab.* **12**, 442–451, https://doi.org/10.1111/j.1463-1326.2010.01204.x
- 49 Wenying, Y., Yanfen, G., Shentu, Y. et al. (2012) The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. *J. Diabetes* **4**, 227–237, https://doi.org/10.1111/j.1753-0407.2012.00213.x
- 50 Yoon, K.H., Shockey, G.R., Teng, R. et al. (2011) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. *Int. J. Clin. Pract.* **65**, 154–164, https://doi.org/10.1111/j.1742-1241.2010.02589.x
- 51 Yoon, K.H., Steinberg, H., Teng, R. et al. (2012) Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. *Diabetes Obes. Metab.* **14**, 745–752, https://doi.org/10.1111/j.1463-1326.2012.01594.x
- 52 Zang, L., Liu, Y., Geng, J. et al. (2016) Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. *Diabetes Obes. Metab.* **18**, 803–811, https://doi.org/10.1111/dom.12674
- 53 Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J. et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* **378**, 31–40, https://doi.org/10.1016/S0140-6736(11)60679-X
- 54 Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N. Engl. J. Med.* **356**, 2457–2471, https://doi.org/10.1056/NEJMoa072761
- 55 Cho, E., Rimm, E.B., Stampfer, M.J., Willett, W.C. and Hu, F.B. (2002) The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J. Am. Coll. Cardiol. 40, 954–960, https://doi.org/10.1016/S0735-1097(02)02044-2
- 56 Schernthaner, G., Barnett, A.H., Emser, A., Patel, S., Troost, J., Woerle, H.J. et al. (2012) Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. *Diabetes Obes. Metab.* **14**, 470–478, https://doi.org/10.1111/j.1463-1326.2012.01565.x
- 57 Williams-Herman, D., Engel, S.S., Round, E., Johnson, J., Golm, G.T., Guo, H. et al. (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. *BMC Endocr. Disord.* **10**, 7, https://doi.org/10.1186/1472-6823-10-7
- 58 Bergman, A.J., Cote, J., Yi, B. et al. (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. *Diabetes Care* **30**, 1862–1864, https://doi.org/10.2337/dc06-2545
- 59 Mari, A., Sallas, W.M., He, Y.L. et al. (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. **90**, 4888–4894, https://doi.org/10.1210/jc.2004-2460
- 60 Rosenstock, J., Sankoh, S. and List J, F. (2008) Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. *Diabetes Obes. Metab.* **10**, 376–386, https://doi.org/10.1111/j.1463-1326.2008.00876.x
- 61 Scott, R., Loeys, T., Davies, M.J. et al. (2008) Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes. Metab.* **10**, 959–969, https://doi.org/10.1111/j.1463-1326.2007.00839.x
- 62 Zhou, X., Ding, L., Liu, J. et al. (2019) Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial. *Endocr. Connect.* **8**, 318–325, https://doi.org/10.1530/EC-18-0523
- 63 Augeri, D.J., Robl, J.A., Betebenner, D.A. et al. (2005) Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48, 5025–5037, https://doi.org/10.1021/jm050261p
- 64 Kohler, S., Salsali, A., Hantel, S. et al. (2016) Safety and tolerability of Empagliflozin in patients with Type 2 diabetes. *Clin. Ther.* **38**, 1299–1313, https://doi.org/10.1016/j.clinthera.2016.03.031